TABLE 1.

Immunologic and virologic characteristics of the study patients

Patient no.Patient identification no.Age (yr)T-cell countVirus load (RNA copies/ml)Treatment history (no. of drugs/duration [months])aVirologic/immunologic responseb
CD4CD8
%Absolute%Absolute
167500012080.2373,713282,785125,482NoneNA
267500009642.0171,420393,178<503/24+/−
367500011542.61944325590141,2132/1−/−
467500011463.220715421,46614,2582/29−/−
567500010854.9291,067391,55941,000NoneNA
667000001215.8234804493835,1743/20−/−
767500010286.8297083891879,2673/2−/+
867500009467.02350227598<503/9+/−
967500006497.0271,534623,55925,0002/12−/+
1067500009398.033600417495,0283/12+/+
1167500009359.022813441,51496,2163/14−/+
1267000001169.0291,312452,06113,3913/16−/+
1367500007179.032494345261,9531/24+/+
1467500008609.5341,134391,234>750,0003/19−/+
15670000008710.6192772334339,9793/6−/+
16670000011311.826979461,7139723/12+/+
17670000006113.123964451,9286004/3+/−
18670000001113.426633358351,0704/1+/+
19670000012913.738677366379,1612/12−/+
20675000098815.00015202229,0863/14−/−
21675000062615.5381,064491,389128,6282/7−/+
22670000012316.5235353785<504/22+/−
  • a Patients were on combinations of nucleoside reverse transcriptase inhibitors (NRTIs) (zidovudine [AZT], lamivudine [3TC], and didioxyinosine) or on NRTIs plus nonnucleoside reverse transcriptase inhibitors (Nevirapine or Efavirenz) or two NRTIs plus protease inhibitors (nelfinavir, ritonavir, or saquinavir) for two, three, or four drug combinations.

  • b Virologic response was defined as a decrease in plasma HIV RNA of greater than 1.0 log or to undetectable levels or the continued state of an undetectable virus load. Immunologic response was defined as an increase in the percentage of CD4 greater than 10% or the continued maintainance of CD4 T cells at greater than 25%. NA, not applicable.